Is Heart Test Laboratories Inc. Common Stock a good investment? Heart Test Laboratories Inc. Common Stock (HSCS) is currently trading at 4.72 USD. Market analysts have a consensus price target of 10.00 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 0.68. This relatively low multiple may signal that Heart Test Laboratories Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Heart Test Laboratories Inc. Common Stock is expected to release its next earnings report on Dec. 21, 2026. The market consensus estimate for Forward EPS is -1.75.
No, it does not currently pay a dividend.
Heart Test Laboratories Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Dec. 21, 2026. The company currently has a trailing EPS of -2.76.
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
| Split Date | Split Ratio to 1 |
|---|---|
| May 17, 2024 | 1:100 |
Community Discussion